Section Arrow
ATYR.NASDAQ
- aTyr Pharma Inc
(Financial Status)
Quotes are at least 15-min delayed:2026/07/15 17:41 EDT
After Hours
Last
 0.5498
+0.0155 (+2.90%)
Bid
0.535
Ask
0.55
High 0.5552 
Low 0.52 
Volume 14.16K 
Regular Hours (Closed)
Last
 0.5343
+0.0483 (+9.94%)
Day High 
0.561 
Prev. Close
0.486 
1-M High
0.6998 
Volume 
6.25M 
Bid
0.535
Ask
0.55
Day Low
0.5 
Open
0.5235 
1-M Low
0.4408 
Market Cap 
47.65M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 0.58 
20-SMA 0.54 
50-SMA 0.57 
52-W High 7.2904 
52-W Low 0.395 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.74/-0.47
Enterprise Value
58.22M
Balance Sheet
Book Value Per Share
0.59
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
190.00K
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
VIVSVivoSim Lab Inc0.8529+0.0181+2.17%0.47PE
After Hours 0.8199 -0.033 -3.87%
LIMNLiminatus Pharma Inc0.1145+0.011+10.63%-- 
After Hours 0.119 +0.0045 +3.93%
IOVAIovance Biotherapeutics4.74+0.81+20.61%-- 
After Hours 4.71 -0.03 -0.63%
ERNAErnexa Therapeutics Inc.6.73+0.67+11.06%0.01PE
After Hours 7.19 +0.46 +6.84%
PHIOPhio Pharmaceuticals Corp0.8901-0.1399-13.58%-- 
After Hours 0.9161 +0.026 +2.92%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.